teaser
Following a comprehensive analysis of pre- and postmarketing data by the UK’s MHRA and Commission on Human Medicines, the risk-benefit profile for rosuvastatin (Crestor
Published on 6 July 2007
Rosuvastatin freed from black triangle
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
